Resumen de acción TSOI Soluciones Terapéuticas Internacionales, Inc. Saber más
Análisis de riesgos + 2 riesgos adicionales
Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Therapeutic Solutions International, Inc. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Therapeutic Solutions International Precios históricos de las acciones Precio actual de la acción US$0.00025 Máximo en las últimas 52 semanas US$0.0019 Mínimo de 52 semanas US$0.0002 Beta 1.37 Cambio en 1 mes -64.29% Variación en 3 meses -68.75% Cambio de 1 año -79.17% Variación en 3 años -98.80% Variación en 5 años -92.86% Variación desde la OPV -99.83%
Noticias y actualizaciones recientes Therapeutic Solutions International, Inc. announced delayed 10-Q filing Nov 15
Therapeutic Solutions International, Inc. announced delayed 10-Q filing Aug 16 Therapeutic Solutions International, Inc. announced delayed 10-Q filing May 17
Therapeutic Solutions International, Inc. announced delayed annual 10-K filing Apr 02
Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients Mar 05
Therapeutic Solutions International, Inc. Announces Successful First Treatment of Patient with FloraStilbene Oct 21 Ver más actualizaciones Therapeutic Solutions International, Inc. announced delayed 10-Q filing Nov 15
Therapeutic Solutions International, Inc. announced delayed 10-Q filing Aug 16 Therapeutic Solutions International, Inc. announced delayed 10-Q filing May 17
Therapeutic Solutions International, Inc. announced delayed annual 10-K filing Apr 02
Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients Mar 05
Therapeutic Solutions International, Inc. Announces Successful First Treatment of Patient with FloraStilbene Oct 21
Res Nova Bio Appoints George Delgado to Scientific Advisory Board Oct 18
Therapeutic Solutions International, Inc. Announces Paradigm Shifting Immunotherapy Product: Tolerogenic Neutrophils Oct 01
Therapeutic Solutions International Appoints Navneet Boddu to Scientific Advisory Board Sep 19
Therapeutic Solutions International, Inc. Announces FlorStilbene™? Demonstrates Synergy with Conventional Chemotherapy and Immunotherapy in Reducing Triple Negative Breast Cancer Aug 22 Allogen Biologics Inc. Successfully Manufactures JadiCell
Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene™ Jul 21
Therapeutic Solutions International, Inc. announced delayed 10-Q filing May 17
Therapeutic Solutions International, Inc. announced delayed 10-Q filing Nov 16
Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease Nov 15
Therapeutic Solutions International Announces Successful Treatment of Epilepsy in Animal Model and Complete Cessation of Seizures in Treatment Resistant Patient Oct 25
Therapeutic Solutions International Identifies Cd103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for Jadicell Mesenchymal Stem Cell Mediated Lung Protection Oct 06 Therapeutic Solutions International, Inc. announced that it expects to receive $10 million in funding from GHS Investments, LLC Sep 21
Therapeutic Solutions International Announces Positive Data and Filing of Patent Covering the Use of Campbellcell for Treatment of Bipolar Disorder by the Company’S Suicide Prevention Based Spin-Off Campbell Neurosciences Sep 20
Therapeutic Solutions International Develops Post Jadicell Maintenance Therapy for Chronic Obstructive Pulmonary Disease Sep 13
Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome Aug 30
Therapeutic Solutions International Files with FDA to Expand ongoing Phase III Clinical Trial to Include All Causes of Acute Respiratory Distress Syndrome Aug 26
Therapeutic Solutions International, Inc. announced delayed 10-Q filing Aug 16
Therapeutic Solutions International, Inc. Reports Superior Efficacy of ApoptoCyte™ on Chronic Obstructive Pulmonary Disease Model Compared to Conventional Stem Cell Approaches Aug 13
Therapeutic Solutions International Creates Disease Specific Therapeutic Platform Based on Gene Editing/Engineering of Inducible Pluripotent Stem Cells Jul 29
Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell™ Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial Jul 19
Therapeutic Solutions International Appoints Donald Banerji to Scientific Advisory Board May 26
Therapeutic Solutions International Receives IND Number 28508 for Chronic Obstructive Pulmonary Disease Clinical Trial and Enters Binding Discussions with FDA for Initiation of Phase I/II Clinical Trial May 24 Therapeutic Solutions International, Inc. announced delayed 10-Q filing May 17
Therapeutic Solutions International Announces New Data Demonstrating Enhancement of Therapeutic Activities of the Jadicell May 13 Therapeutic Solutions International, Inc. Files Investigational New Drug Application May 10
Therapeutic Solutions International, Inc. Announces Launching of Phase III Clinical Trial for Treating Covid-19 Lung Damage Using its Jadicell Universal Donor Stem Cell Drug May 03
Therapeutic Solutions International Identifies Novel Biological Pathway Apr 20
Therapeutic Solutions International Announces Reduction of COVID-19 Associated Cognitive Decline by QuadraMune® Nutraceutical in Animal Model Feb 08
Therapeutic Solutions International Reports Positive Clinical Data on QuadraMune® Reduction of SARS-CoV-2 Spike Protein Induced Inflammation Jan 04
Therapeutic Solutions International Successfully Treats No Option Patients with its JadiCell Stem Cell Therapy While Advancing Preparations for Phase III COVID-19 Clinical Trial Dec 31
Therapeutic Solutions International, Inc. Receives Patent for Cancer and COVID-19 Treatment Dec 29
Therapeutic Solutions International, Inc. Discovers and Files Patent on Novel Cellular Therapy Combination for Augmentation of Lung Repair in Covid-19 Model Sep 24
Therapeutic Solutions International Successfully Treats Veteran Navy Seal Suffering from Chronic Traumatic Encephalopathy with Jadicell™ Adult Stem Cells Under Right to Try Law Sep 14
Therapeutic Solutions International, Inc. Files Investigational New Drug Application with FDA for Cancer Blood Vessel Targeting Immunotherapy StemVacs-V to Treat Metastatic Breast Cancer Aug 31
Therapeutic Solutions International, Inc. Announces Positive Preclinical Results Using Jadicells™ in Animal Model of Chronic Obstructive Pulmonary Failure (COPD) Aug 24
Therapeutic Solutions International, Inc. Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Aug 12
Therapeutic Solutions International Completes FDA Requested Studies to Initiate JadiCell™ Chronic Traumatic Encephalopathy (CTE) Clinical Trial Aug 10
Therapeutic Solutions International, Inc. Receives FDA Clearance to Initiate Phase III Pivotal Registration Trial for JadiCell™ Universal Donor COVID-19 Therapy Aug 06
Therapeutic Solutions International, Inc. Spin-Off Campbell Neurosciences Initiates Pilot Implementation of Campbell Score™ with California Concierge Medical & Wellness Inc Jul 03
Therapeutic Solutions International Demonstrates Potent Brain Protective Activity of JadiCells in Animal Model of Post-Covid-19 Neurological Damage Jul 01
Therapeutic Solutions Reports Synergistic Reduction of Schizophrenia in Animal Models Using Low Dose Naltrexone and T Regulatory Cell Stimulation Jun 17
Therapeutic Solutions International Reports Amplification of Cancer Specific Immune Responses Using Second Generation Tumor Endothelial Targeting Vaccine StemVacs-V iPSC Jun 08
Therapeutic Solutions International Subsidiary Campbell Neurosciences Identifies T Regulatory Cells as Mechanism of Stem Cell Suppression of Schizophrenia Pathology in an Animal Model Jun 03
Therapeutic Solutions International, Inc. Announces New Data Demonstrating Synergy Between its Tumor Blood Vessel Killing Vaccine, StemVacs-V iPSC and Specific Immunological Adjuvants May 25
Therapeutic Solutions International, Inc. Develops Novel Stem Cell Based Therapy to Reduce Lung Scarring: Potential Solution to Post COVID-19 Lung Deterioration May 22
Therapeutic Solutions International and Campbell Neurosciences Announce Preclinical Studies Showing Low Doses of FDA Cleared Immune Stimulant Interleukin-2 Reduces Inflammation Associated Depression in Animal Model May 18
Therapeutic Solutions International, Inc. Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low Dose Chemotherapy Apr 27
Therapeutic Solutions International, Inc. announced delayed annual 10-K filing Apr 02
Therapeutic Solutions International Announces Novel Cancer-Resistant iPSC-Derived Dendritic Cell Immunotherapy: StemVacs-V™ Mar 17
Therapeutic Solutions International, Inc. Spin-off Campbell Neurosciences Announces Umbilical Cord Derived Monocyte Immunotherapy Candidate for Suicide Prevention Mar 05
Therapeutic Solutions International Approves on RangeMe to sell QuadraMune™ and NanoStilbene™ Along with Other Supplements Mar 04
Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Preliminary Efficacy of First Blood-Based Test for Gambling Addiction: Kaihani Score™ Feb 26
Therapeutic Solutions International Uses Stemvacs™ Platform to Generate Personalized Adoptive T Cell Therapy Targeting Cancer Stem Cells Feb 23
Therapeutic Solutions International Appoints Dr. Boris Minev to Scientific Advisory Board Feb 18
Therapeutic Solutions International Reports Preliminary Data Suggesting StemVacs Induces Natural Killer Memory to Cancer Feb 09
Therapeutic Solutions International Enters into Master Sales Agreement with Community Shield LLC Feb 05
Therapeutic Solutions International, Inc. Announces Filing of Patent Disclosing Enhancement of Natural Killer Cell and T Cell Activity by Stemvacs After Treatment with Homotaurine, A Safe Blood-Brain Barrier Permeable Gaba A-R-Specific Agonist Jan 28
Therapeutic Solutions International Reports Regression of Glioma, Lung Cancer and Colorectal Cancer using StemVacs in Animal Models Jan 26
Therapeutic Solutions International Reports Successful Treatment of Breast Cancer Using StemVacs Cellular Immunotherapy Jan 20
Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences Jan 14
Therapeutic Solutions International Reports QuadraMune Administration Enhances T Cytotoxic Responses in Mouse Model of Adaptive Immunity Jan 06
Therapeutic Solutions International, Inc. Reports QuadraMune Increases T Cell Immunity in Animal Studies Dec 31
Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using Clinically Validated JadiCell® Universal Donor Stem Cell Dec 19 Therapeutic Solutions International Announces Clinical Trial Assessing "Kaihani Score" Proprietary Biomarker Based Assay for Quantifying Gambling Addiction Therapeutic Solutions International, Inc. announced delayed 10-Q filing Nov 18
Therapeutic Solutions International, Inc. Reports Augmentation of Immunotherapy Efficacy in Breast Cancer Model Utilizing Patented NanoStilbene Nutraceutical Product Nov 11
Therapeutic Solutions International Launches Clinical Trial to Validate First Blood Based Predicator of Suicidal Ideation: The Campbell Score Oct 30
Therapeutics Solution International, Inc. Reports Positive Preclinical Data on Multiple Sclerosis using NanoStilbene Oct 20
Therapeutic Solutions International Appoints Serena Robella as Director of Sales Oct 13 Rentabilidad de los accionistas TSOI US Pharmaceuticals Mercado US 7D -37.5% -0.3% -2.7% 1Y -79.2% 7.9% 23.4%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: Los resultados de TSOI fueron inferiores a los de la industria US Pharmaceuticals, que obtuvo un rendimiento del 7.9% el año pasado.
Rentabilidad vs. Mercado: TSOI obtuvo unos resultados inferiores a los del mercado US, que fueron del 23.4% el año pasado.
Volatilidad de los precios Is TSOI's price volatile compared to industry and market? TSOI volatility TSOI Average Weekly Movement 25.6% Pharmaceuticals Industry Average Movement 10.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.9% 10% least volatile stocks in US Market 3.2%
Precio estable de las acciones: El precio de las acciones de TSOI ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de TSOI(26%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa Therapeutic Solutions International, Inc. se centra en la modulación inmunitaria para el tratamiento de diversas enfermedades específicas en Estados Unidos. La empresa desarrolla una gama de agentes inmunomoduladores contra el cáncer, la esquizofrenia, la ideación suicida y las lesiones cerebrales traumáticas, así como para la salud cotidiana. Sus productos estrella son QuadraMune, una mezcla sinérgica patentada de pterostilbeno, sulforafano, epigalocatequingalato y timoquionona para aumentar la actividad de las células asesinas naturales y la producción de citocinas saludables.
Mostrar más Resumen de fundamentos de Therapeutic Solutions International, Inc. ¿Cómo se comparan los beneficios e ingresos de Therapeutic Solutions International con su capitalización de mercado? Estadísticas fundamentales de TSOI Capitalización bursátil US$1.28m Beneficios(TTM ) -US$2.41m Ingresos (TTM ) US$85.32k
15.0x Ratio precio-ventas (PS)
-0.5x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de TSOI Ingresos US$85.32k Coste de los ingresos US$29.18k Beneficio bruto US$56.14k Otros gastos US$2.47m Beneficios -US$2.41m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.00047 Margen bruto 65.80% Margen de beneficio neto -2,824.94% Ratio deuda/patrimonio 49.0%
¿Cómo se ha desempeñado TSOI a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/23 13:21 Precio de las acciones al final del día 2024/12/20 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Therapeutic Solutions International, Inc. está cubierta por 0 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
